Abstract
Aim
To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.Methods
After a screening, diet/exercise run-in and drug wash-off period, a glimepiride +/- metformin dose titration/stabilization period and a 2-week, single-blind placebo run-in, 441 patients (of ages 18-75 years) were randomized to receive the addition of sitagliptin 100 mg once daily or placebo in a 1 : 1 ratio for 24 weeks. Of these patients, 212 were on glimepiride (>or=4 mg/day) monotherapy and 229 were on glimepiride (>or=4 mg/day) plus metformin (>or=1,500 mg/day) combination therapy. Patients exceeding pre-specified glycaemic thresholds during the double-blind treatment period were provided open-label rescue therapy (pioglitazone) until study end. The primary efficacy analysis evaluated the change in HbA(1c) from baseline to Week 24. Secondary efficacy endpoints included fasting plasma glucose (FPG), 2-h post-meal glucose and lipid measurements.Results
Mean baseline HbA(1c) was 8.34% in the sitagliptin and placebo groups. After 24 weeks, sitagliptin reduced HbA(1c) by 0.74% (p < 0.001) relative to placebo. In the subset of patients on glimepiride plus metformin, sitagliptin reduced HbA(1c) by 0.89% relative to placebo, compared with a reduction of 0.57% in the subset of patients on glimepiride alone. The addition of sitagliptin reduced FPG by 20.1 mg/dl (p < 0.001) and increased homeostasis model assessment-beta, a marker of beta-cell function, by 12% (p < 0.05) relative to placebo. In patients who underwent a meal tolerance test (n = 134), sitagliptin decreased 2-h post-prandial glucose (PPG) by 36.1 mg/dl (p < 0.001) relative to placebo. The addition of sitagliptin was generally well tolerated, although there was a higher incidence of overall (60 vs. 47%) and drug-related adverse experiences (AEs) (15 vs. 7%) in the sitagliptin group than in the placebo group. This was largely because of a higher incidence of hypoglycaemia AEs (12 vs. 2%, respectively) in the sitagliptin group compared with the placebo group. Body weight modestly increased with sitagliptin relative to placebo (+0.8 vs. -0.4 kg; p < 0.001).Conclusions
Sitagliptin 100 mg once daily significantly improved glycaemic control and beta-cell function in patients with type 2 diabetes who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy. The addition of sitagliptin was generally well tolerated, with a modest increase in hypoglycaemia and body weight, consistent with glimepiride therapy and the observed degree of glycaemic improvement.Full text links
Read article at publisher's site: https://doi.org/10.1111/j.1463-1326.2007.00744.x
Read article for free, from open access legal sources, via Unpaywall:
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1463-1326.2007.00744.x
References
Articles referenced by this article (23)
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
JAMA, (21):2005-2012 1999
MED: 10359389
Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus.
Br Med J, (6008):498-500 1976
MED: 814956
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Diabetes, (12):2063-2069 2000
MED: 11118008
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
N Engl J Med, (13):867-872 1998
MED: 9516221
Title not supplied
2006
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Diabetes, (11):1663-1670 1998
MED: 9792533
Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Expert Opin Investig Drugs, (9):1091-1102 2004
MED: 15330741
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Clin Pharmacol Ther, (6):675-688 2005
MED: 16338283
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Clin Ther, (1):55-72 2006
MED: 16490580
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
J Clin Endocrinol Metab, (11):4612-4619 2006
MED: 16912128
Show 10 more references (10 of 23)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1111/j.1463-1326.2007.00744.x
Article citations
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
Diabetes Ther, 15(6):1403-1416, 24 Apr 2024
Cited by: 0 articles | PMID: 38653904 | PMCID: PMC11096144
Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients.
BMC Endocr Disord, 23(1):244, 08 Nov 2023
Cited by: 0 articles | PMID: 37940936 | PMCID: PMC10631090
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
Diabetes Ther, 14(9):1517-1535, 06 Jul 2023
Cited by: 2 articles | PMID: 37410308 | PMCID: PMC10363101
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature.
Front Mol Biosci, 10:1130625, 23 May 2023
Cited by: 11 articles | PMID: 37287751 | PMCID: PMC10242023
Review Free full text in Europe PMC
Influence of glimepiride plus sitagliptin on treatment outcome, blood glucose, and oxidative stress in diabetic patients.
Am J Transl Res, 14(10):7459-7466, 15 Oct 2022
Cited by: 2 articles | PMID: 36398218 | PMCID: PMC9641479
Go to all (311) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Clin Ther, 28(10):1556-1568, 01 Oct 2006
Cited by: 307 articles | PMID: 17157112
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Diabetes Obes Metab, 9(2):186-193, 01 Mar 2007
Cited by: 98 articles | PMID: 17300594
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
J Assoc Physicians India, 60:27-30, 01 Mar 2012
Cited by: 14 articles | PMID: 22799111
Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Cardiol Rev, 15(5):264-271, 01 Sep 2007
Cited by: 22 articles | PMID: 17700385
Review
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Expert Opin Investig Drugs, 19(8):1017-1025, 01 Aug 2010
Cited by: 9 articles | PMID: 20629618
Review